Rui-Ping Dong

Functional Interaction of DFF35 and DFF45 with Caspase-activated DNA Fragmentation Nuclease DFF40

Jijie Gu, Rui-Ping Dong, Chonghui Zhang et al. · Journal of Biological Chemistry · 1999 · 80 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +15

A phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145

Michael J. Kovacs, Donna Reece, Deborah Marcellus et al. · Investigational New Drugs · 2006 · 75 citations

Medicine, Oncology, Pharmacology +13

<scp>First-in-Human</scp> Phase I Study of Envafolimab, a Novel Subcutaneous <scp>Single-Domain Anti-PD-L1</scp> Antibody, in Patients with Advanced Solid Tumors

Kyriakos P. Papadopoulos, Wael A. Harb, Cody J. Peer et al. · The Oncologist · 2021 · 75 citations · Full text

Pharmacy, Oncology, Pharmacology +17

HLA-A and -DRB4 genes in controlling the susceptibility to Hashimoto's thyroiditis

Xiao-Lin Wan, Akinori Kimura, Rui-Ping Dong et al. · Human Immunology · 1995 · 54 citations

Life Sciences, Genetics, Immunology +12

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone et al. · Journal of Clinical Oncology · 2023 · 52 citations

Medicine, Oncology, Pharmacology +13